Tracing the start of COVID-19 in GA

At a time when COVID-19 appears to be receding in much of Georgia, it’s worth revisiting the start of the pandemic in early 2020. Emory virologist Anne Piantadosi and colleagues have a paper in Viral Evolution on the earliest SARS-CoV-2 genetic sequences detected in Georgia. Analyzing relationships between those virus sequences and samples from other states and countries can give us an idea about where the first COVID-19 infections in Georgia came from. We can draw Read more

Reddit as window into opioid withdrawal strategies

Drug abuse researchers are using the social media site Reddit as a window into the experiences of people living with opioid addiction. Abeed Sarker in Emory's Department of Biomedical Informatics has a paper in Clinical Toxicology focusing on the phenomenon of “precipitated withdrawal,” in collaboration with emergency medicine specialists from Penn, Rutgers and Mt Sinai. Precipitated withdrawal is a more intense form of withdrawal that can occur when someone who was using opioids starts medication-assisted treatment Read more

CROI: HIV cure report and ongoing research

The big news out of CROI (Conference on Retroviruses and Opportunistic Infections) was a report of a third person being cured of HIV infection, this time using umbilical cord blood for a hematopoetic stem cell transplant. Emory’s Carlos del Rio gave a nice overview of the achievement for NPR this morning. As del Rio explains, the field of HIV cure research took off over the last decade after Timothy Brown, known as “the Berlin patient,” Read more

kinase

Tangled up with tau

Pathologist Keqiang Ye and his colleagues have identified a new potential drug target in Alzheimer’s disease. It’s called SRPK2 (serine-arginine protein kinase 2).

Keqiang Ye, PhD

Depleting this enzyme from the brain using genetic engineering tools alleviates cognitive impairment in an animal model of Alzheimer’s. The result suggests that drugs Cheap Oakleys that target this enzyme could be valuable in the treatment of Alzheimer’s, although additional studies on human brain samples are necessary to fully confirm the findings, Ye says.

The results were published Tuesday in Journal of Neuroscience. The first author is postdoctoral fellow Yi Hong.

Hong and colleagues found that SRPK2 has elevated activity in a mouse model of Alzheimer’s. It acts on tau, one of the two major toxic clumpy proteins in Alzheimer’s. (beta-amyloid is outside the cell and forms plaques, tau is inside and forms tangles). Previous research on SRPK2 indicated that it had something to do with RNA splicing, so its “entanglement” with tau is a surprise.

Posted on by Quinn Eastman in Neuro Leave a comment